Benzimidazole compound abrogates SARS-COV-2 receptor-binding domain (RBD)/ACE2 interaction In vitro

The development of clinically actionable pharmaceuticals against coronavirus disease (COVID-19); an infectious disease caused by the SARS-CoV-2 virus is very important for ending the pandemic. Coronavirus spike glycoprotein (GP)-Receptor Binding Domain (RBD) and its interaction with host receptor an...

Descripción completa

Detalles Bibliográficos
Autores principales: Omotuyi, Olaposi, Olatunji, Olusina M., Nash, Oyekanmi, Oyinloye, Babatunji, Soremekun, Opeyemi, Ijagbuji, Ayodeji, Fatumo, Segun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851952/
https://www.ncbi.nlm.nih.gov/pubmed/36682669
http://dx.doi.org/10.1016/j.micpath.2023.105994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851952/
https://www.ncbi.nlm.nih.gov/pubmed/36682669
http://dx.doi.org/10.1016/j.micpath.2023.105994

Ejemplares similares